Orexo
18.86 SEK
-0.32 %
Less than 1K followers
ORX
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Valuation
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Orexo
P/E
Median 2019-2025
EV/S
Median 2019-2024
EV/EBIT
Median 2019-2024
P/B
Median 2019-2025
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Share price (SEK) | 62.80 | 50.00 | 34.50 | 18.86 | 15.46 | 17.50 | 30.10 |
| Shares | 34.6 | 34.6 | 34.3 | 34.4 | 34.4 | 34.5 | 34.7 |
| Market cap | 2,174.2 | 1,731.1 | 1,184.5 | 648.2 | 532.6 | 603.8 | 1,044.6 |
| Enterprise value | 1,647.0 | 1,450.3 | 1,230.9 | 836.0 | 835.4 | 956.5 | - |
| EV/S | 1.9 | 2.2 | 2.2 | 1.3 | 1.3 | 1.6 | - |
| EV/EBITDA | 6.1 | 76.3 | neg. | neg. | neg. | 40.9 | - |
| EV/EBIT | 7.1 | neg. | neg. | neg. | neg. | neg. | - |
| P/E | 9.9 | neg. | neg. | neg. | neg. | neg. | 1.6 |
| P/B | 3.08 | 3.10 | 3.39 | 3.34 | 9.04 | -4.78 | 2.13 |
| P/S | 2.6 | 2.6 | 2.1 | 1.0 | 0.8 | 1.0 | 40.2 |
| Dividend yield | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
| Equity ratio | 47.1 % | 45.3 % | 27.4 % | 17.5 % | 7.5 % | -21.2 % | 37.7 % |
| Gearing ratio | 48.7 % | 48.7 % | 157.5 % | 278.3 % | 804.4 % | -376.9 % | 100.2 % |